These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 26813119)

  • 1. From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.
    Busardò FP; Kyriakou C; Cipolloni L; Zaami S; Frati P
    Curr Neuropharmacol; 2016; 14(1):17-27. PubMed ID: 26813119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
    Kollins SH
    J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence.
    Godfrey J
    J Psychopharmacol; 2009 Mar; 23(2):194-205. PubMed ID: 18515459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misuse of Methylphenidate.
    Clemow DB
    Curr Top Behav Neurosci; 2017; 34():99-124. PubMed ID: 26695166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there stimulant sensitivity in children?
    Klein R; Mannuzza S
    J Atten Disord; 2002; 6 Suppl 1():S61-3. PubMed ID: 12685520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Methylphenidate misuse].
    Bruggisser M; Bodmer M; Liechti ME
    Praxis (Bern 1994); 2012 Feb; 101(5):299-305. PubMed ID: 22377977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
    Bricard C; Boidein F
    Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.
    Williams RJ; Goodale LA; Shay-Fiddler MA; Gloster SP; Chang SY
    Am J Addict; 2004; 13(4):381-9. PubMed ID: 15370936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Students' stimulant use for cognitive enhancement: A deliberate choice rather than an emotional response to a given situation.
    Ponnet K; Tholen R; De Bruyn S; Wouters E; Van Ouytsel J; Walrave M; Van Hal G
    Drug Alcohol Depend; 2021 Jan; 218():108410. PubMed ID: 33250387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
    Simon N; Rolland B; Karila L
    Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of treatment-induced insomnia in ADHD.
    Kratochvil CJ; Lake M; Pliszka SR; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):499-501. PubMed ID: 15843773
    [No Abstract]   [Full Text] [Related]  

  • 20. Attention deficit and hyperactivity disorder in people with epilepsy: diagnosis and implications to the treatment.
    Koneski JA; Casella EB
    Arq Neuropsiquiatr; 2010 Feb; 68(1):107-14. PubMed ID: 20339664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.